{"id":"W4408978958","doi":"10.1016/s1556-0864(25)00197-2","title":"2O: SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and METoverexpression (OverExp) and/or amplification (Amp) following progressive disease (PD) on osi","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Osimertinib; Internal medicine; Oncology; Disease; Adenocarcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005264876,0.0003035681,0.0005867698,0.0002415099,0.0002986125,0.0006479229,0.0002885283,0.0007295531,0.0144532],"category_scores_gemma":[0.0005765125,0.0001418875,0.0007349842,0.0002173703,0.0002645161,0.0004921232,0.0002843406,0.0009035668,0.001326884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006445355,"about_ca_system_score_gemma":0.0009091751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007165553,"about_ca_topic_score_gemma":0.004023393,"domain_scores_codex":[0.9997827,0.00006540209,0.00001879921,0.00003773483,0.00002217978,0.00007317907],"domain_scores_gemma":[0.9997702,0.00003585947,0.0000385277,0.000008873616,0.00001232277,0.000134329],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4868407,0.006465559,0.06561157,0.001539839,0.001404501,0.0009429011,0.0002164825,0.001354664,0.02397288,0.001840354,0.03452784,0.3752826],"study_design_scores_gemma":[0.2317829,0.2552823,0.3360738,0.001092552,0.003049604,0.004059266,0.0004499319,0.005078267,0.01472315,0.002147551,0.1461037,0.0001570798],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9699127,0.005789784,0.0002448884,0.002548401,0.0006281298,0.0006073999,0.002115765,0.0001530312,0.01799991],"genre_scores_gemma":[0.9873201,0.001426417,0.0005527822,0.0009273561,0.0003058809,0.0003169038,0.001720624,0.00002001425,0.007409919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0144532,"threshold_uncertainty_score":0.04835075,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01685733822627303,"score_gpt":0.4293698245302836,"score_spread":0.4125124863040106,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}